An idiographic that explains the absorption and bioavailability of fentanyl with mentor. The idiographic is divided into three sections. The first section is titled "Absorption and Bioavailability" and has a green background with white text. It explains that mentors provides greater bioavailability than action (fentanyl citrate) oral transmucosal lozenge CII and CII. The second section has a table that shows the percentage of people who have been diagnosed with fentanyl. The table has three columns - 48% of the people who are diagnosed with the condition 22% of those who have experienced the condition. The third column has a bar graph that shows that the percentage is higher than the rest of the table. The fourth column has an image of a person's face and the text reads "mentor uses opalescent Technology". At the bottom of the idiographic there is a link to the website "mentor.com" and a button to proceed to the next page. The website's logo is also visible in the top left corner.
Description 
Type
Category
Source 1 of 3
-
Date
2014
Collection
-
Date
2014
Collection
-
Date
2014
Collection
We encourage you to view the image in the context of its source document(s) and cite the source(s) when using these images. However, to cite just this image alone, click the “Cite This Image” button and then paste the copied text.
![A screenshot from the Exalgo website. It appears to show case studies for how to convert different example patients to Exalgo step-by-step. The website is of example patient Dennis and the "Dose Conversion" step is selected. The website has a blue and white color scheme with a blue header and black footer.<br /><br />The main text of the page reads "Exalgo could give Dennis the pain relief he wants - with a once-daily dose. Double-blind placebo-controlled withdrawal study of opioid-tolerant patients with low back pain (447 enrolled 268 randomized; 66[49%] EXALGO patients and 44 [31%) placebo patients completed the study". Below that there is additional section titled "Double-blind treatment phase" which provides more information about the study and shows a bar graph comparing a reduction in pain intensity scores for Exalgo patients as compared with a placebo. <br /><br />The bottom of the page also has important risk information. In the lower right corner there is an image of a person walking a dog on a leash with a tree in the background. The footer has the Exalgo logo and a navigation menu.](https://oida-resources-images.azureedge.net/public/full/e3632038-48ef-4cfd-bf64-2e725bffad73.png)
![A flowchart that shows the steps involved in the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery. The flowchart is divided into six phases each with a different color and label.<br /><br />The first phase is labeled "Preliminary Phase 1" and is followed by "Phase 2" and "Phase 3" [etc.]](https://oida-resources-images.azureedge.net/public/full/312d2522-d393-4c78-bc97-eecabd457887.JPG)
